lincR-Ccr2-5′AS and THRIL as potential biomarkers of multiple sclerosis

Egyptian Journal of Medical Human Genetics

Table 3 Relative expression levels of LincR-Ccr2-5′As and THRIL based on different clinical characters among cases

	LincR-Ccr2-5′As, fold change (2^−ΔΔCt), mean± SE	p-value	THRIL, fold change (2^−ΔΔCt), mean± SE	p-value
Types
RRMS	1.08±0.49	0.2	7.91±2.7	0.04
SPMS	0.057±0.24	0.2	1.84±0.83	0.04
Initial presentation
Optic neuritis	0.622±0.25	0.001	4.91±4.2	0.01^a
Sensory	4.1±0.91		1.69±0.79	0.05^b
Motor	0.59±0.12		8.1±2.8	0.001^c
EDSS score [mean ±SD]
EDSS=1–3	0.64±0.5	0.01^a	6.75±3.3	0.02^d
EDSS=3.5–5	1.13±0.8	0.001^b,c	9.5±4.5	0.001^e,f
EDSS ≥ 5.5	0.11±0.2		2.34±0.9
Treatment
Treatment-naive	0.17±0.4	0.001^d,e,f	6.84±5	0.001^g,h
Interferon	1.45±0.6		7.1±2.8	0.9ⁱ
Immunosuppressants	0.38±0.1		2.81	0.9ⁱ

^aBetween patients with EDSS=1–3 and EDSS=3.5–5
^bBetween patients with EDSS=1–3 and EDSS ≥ 5.5
^cBetween patients with EDSS=3.5–5 and EDSS ≥ 5.5
^dBetween patients on interferon and immunosuppressant
^eBetween patients on interferon and treatment naive patients
^fBetween patients on immunosuppressant and treatment naive patients, ^g,hbetween treatment naive and patients on immunsuppressant,i between treatment naive and patients on interferon